摘要
目的探讨人参皂苷Re是否通过促进肠道中胰高血糖素样肽-1的分泌来发挥抗糖尿病的药理机制。方法雄性SD大鼠腹腔注射链脲佐菌素,结合高糖、高脂饮食4周后,测定空腹血糖。将造模成功的动物随机分成4组,即模型对照组,人参皂苷Re50,100mg/kg治疗组和正常对照组。连续灌胃治疗4周,在治疗期间每周测1次血糖并监测摄食量。治疗4周后,各组大鼠禁食8h,治疗组给药30min后给予葡萄糖溶液3g/kg,腹腔注射戊巴比妥钠麻醉。糖负荷后15min,取大鼠的肝门静脉血、回肠和结肠组织,分别用酶联免疫吸附试验(ELISA)测定血浆中的胰岛素含量及血浆、回肠、结肠组织中的胰高血糖素样肽-1的含量。另取一部分回肠组织用ELISA测定胰高血糖素原分泌水平。结果相对于糖尿病模型组,无论是血浆或肠道组织,人参皂苷Re治疗组显著增加了胰高血糖素样肽-1的分泌,实验还显示治疗组显著增加了血浆中胰岛素的含量、降低了血糖和摄食量,改善了糖尿病症状。结论人参皂苷Re可能通过促进肠道组织中胰高血糖素样肽-1的分泌来发挥降血糖、治疗糖尿病的作用。
Objective To investigate whether Ginsenoside Re, an agent that is definitely hypoglycemic but poorly absorbed and has a low blood level after oral use, exerts its anti-diabetic effects via modulating GLP-1 secretion. Methods Diabetes was induced in male SD rats by intraperitoneal injection of streptozotocin. The rats were fed on high-glucose high-fat diet for 4 weeks, and then measured for fasting blood glucose. Thereafter, the model rats were randomized into 4 groups： the model control group, 50 mg/kg and 100 mg/kg Re treated groups, and the normal control group, to receive continuous gavage for 4 weeks. During the 4-week treatment, blood glucose was measured and food intake was recorded for the rats once weekly. At 4 weeks later, the rats were subjected to an 8-hour fasting, followed by 3 g/kg glucose gavage, and anaesthesia with intraperitoneal phenobarbital. At 15 minutes after glucose load, blood samples and intestines were obtained to measure insulin and GLP-1 using ELISA kit. The level of proglucagon in the ileum was measured by ELISA. Results Ginsenoside Re treatment significantly increased GLP-1 levels in plasma and intestine （P0.05） accompanied with the increase of proglucagon level compared with the controls （P0.05）. Furthermore, Ginsenoside Re increased insulin levels in plasma （P0.05）. Conclusion The anti-diabetic effects of Ginsenoside Re may partly result from enhanced GLP-1 secretion in the intestines.
出处
《中国药物与临床》
CAS
2011年第12期1383-1385,共3页
Chinese Remedies & Clinics
基金
中国康复研究中心课题(2010-21)
